OR WAIT null SECS
April 30, 2015.
The global treatment market value for prostate cancer, excluding hormonal and bone therapies, will expand more than threefold from $2.6 billion in 2013 to an estimated $8.2 billion by 2023, according to research and consulting firm GlobalData.
PharmaPoint: Prostate Cancer – Global Drug Forecast and Market Analysis to 2023 reports that the increase - across the nine major markets (9MM), US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada -will be driven by a rapidly aging population, the introduction of nine new, premium-priced therapies by 2023, and the expected label extensions for both Zytiga and Xtandi in the treatment of hormone-sensitive prostate cancer.
GlobalData's Raksha Mudbhary, Ph.D., says that Japan and Brazil will experience particularly impressive market growth during the forecast period, due to the increased screening of prostate cancer resulting in higher incidence in Japan, as well as the introduction of several branded products for the treatment of castration-resistant prostate cancer (CRPC).
However, the analyst notes that the primary driver of growth across the nine major markets for prostate cancer treatment will be the label extension of Xtandi into chemotherapy-naïve metastatic CRPC, non-metastatic CRPC and hormone-sensitive prostate cancer.
Further information here.